Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

NCT02091310 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Placebo
DRUG: GFT505
DRUG: Moxifloxacin 400 mg

Sponsor

Genfit

Collaborators

[object Object]
[object Object]
[object Object]